Multiple myeloma international staging system: "staging" or simply "aging" system?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 6, 2013, Pages 635-637

  Bataille, Regis ^a,b   Annweiler, Cedric ^c,d   Beauchet, Olivier ^c  

^a Nantes St Herblain and Centre de Recherche en Cancérologie et Immunologie   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Albumin; Beta2 microglobulin; Morbidity burden; Mulitple myeloma; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; MELPHALAN; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; THALIDOMIDE DERIVATIVE;

AGING; ATHEROSCLEROSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CARDIOVASCULAR DISEASE; CELL GROWTH; COMORBIDITY; CYTOGENETICS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LABELING INDEX; MORBIDITY; MULTIPLE MYELOMA; MULTIPLE MYELOMA INTERNATIONAL STAGING SYSTEM; MYELOMA CELL; OVERALL SURVIVAL; REVIEW; RISK FACTOR; STANDARD; TUMOR CLASSIFICATION; TUMOR VOLUME;

ALBUMIN; BETA2-MICROGLOBULIN; MORBIDITY BURDEN; MULITPLE MYELOMA; PROGNOSIS;

AGING; BETA 2-MICROGLOBULIN; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84887992534     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.07.003     Document Type: Note

References (32)

1. R.A. Kyle Why better prognostic factors for multiple myeloma are needed Blood 83 1994 1713 1716
2. P.R. Greipp, J. San Miguel, and B.G. Durie International staging system for multiple myeloma J Clin Oncol 23 2005 3414 3420
3. R. Fonseca, and J. San Miguel Prognostic factors and staging in multiple myeloma Hematol Oncol Clin North Am 21 2007 1115 1140
4. D. Norfolk, J.A. Child, and E.H. Cooper Serum B2 microglobulin in myelomatosis potential value in stratification and monitoring Br J Cancer 42 1980 5 10
5. R. Bataille, J. Grenier, and J. Sany Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment. A prospective study of 160 patients Blood 63 1984 468 476
6. H. Avet-Loiseau, M. Attal, and P. Moreau Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood 109 2007 3489 3495
7. R. Bataille, B.G. Durie, and J. Grenier Prognostic factors and staging in multiple myeloma J Clin Oncol 4 1986 80 87
8. B.G. Durie, and S.E. Salmon A clinical staging system for muliple myeloma Cancer 36 1975 842 854
9. B.G. Durie, D. Stock-Novack, and S.E. Salmon Prognostic value of pre-treatment serum B2 microglobulin in myeloma: a Southwest Oncology Group study Blood 75 1990 823 830
10. J.L. Jacobson, M.A. Hussein, and B. Barlogie A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience Br J Haematol 122 2003 441 450
11. O. Decaux, L. Lode, and F. Magrangeas Prediction of survival in multiple myeloma based on gene expression profile reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome J Clin Oncol 26 2008 4798 4805
12. T.B. Bartel, J. Haessler, and T.L. Brown F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Blood 114 2009 2068 2076
13. R. Bataille, B. Barlogie, and Z.Y. Lu Biologic effects of anti-interleukin 6 murine monoclonal antibody in advanced multiple myeloma Blood 86 1995 685 691
14. C. Vincent, J.P. Revillard, and M. Galland Serum beta2-microglobulin in hemodialyzed patients Nephron 21 1978 260 268
15. E. Erez, D. Aravot, and A. Erman Increased production of B2-microglobulin after heart transplantation J Heart Lung Transplant 17 1998 538 541
16. C. Annweiler, R. Bataille, and N. Ferrière Plasma beta-2 microglobulin as a marker of frailty in older adults: a pilot study J Gerontol A Biol Sci Med Sci 66 2011 1077 1079
17. S. Shinkai, S. Kumagai, and Y. Fujiwara Predictors for the onset of functional decline among initially non-disabled older people living in a community during a 6-year follow-up Geriatr Gerontol Int 3 2003 S31 S39
18. S. Shinkai, P.H. Chaves, and Y. Fujiwara Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein Arch Intern Med 168 2008 200 206
19. I. Gom, H. Fukushima, and M. Shiraki Relationship between serum albumin level and aging in community-dwelling self-supported elderly population J Nutr Sci Vitaminol 53 2007 37 42
20. F.R. Herrmann, C. Safran, and S.E. Levkoff Serum albumin level on admission as a predictor of death, length of stay, and readmission Arch Intern Med 152 1992 125 130
21. P. Goldwasser, and J. Feldman Association of serum albumin and mortality risk J Clin Epidemiol 50 1997 693 703
22. M.C. Corti, J.M. Guralnik, and M.E. Salive Serum albumin level and physical disability as predictors of mortality in older persons JAMA 272 1994 1036 1042
23. R.N. Baumgartner, D.L. Waters, and D. Gallagher Predictors of skeletal muscle mass in elderly men and women Mech Ageing Dev 107 1999 123 136
24. H. Ludwig, B.G. Durie, and V. Bolejack Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group Blood 111 2008 4039 4047
25. H. Ludwig, V. Bolejack, and J. Crowley Survival and years of life lost in different age cohorts of patients with Multiple Myeloma J Clin Oncol 28 2010 1599 1605
26. S. Dupire, M. Wemeau, and H. Debarri Prognostic value of PINI index in patients with multiple myeloma Eur J Haematol 88 2012 306 313
27. P.R. Greipp, J.A. Lust, and W.M. O'Fallon Plasma cell labeling index and beta2microglobulin predict survival independent of thymidine-kinase and C-reactive protein in multiple myeloma Blood 81 1993 3382 3387
28. J.D. Shaughnessy, Z. Fenghuang, and B.E. Burington A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood 109 2007 2276 2284
29. Y. Zhou, B. Barlogie, and J.R. Shaughnessy The molecular characterization and clinical management of multiple myeloma in the post-genome era Leukemia 23 2009 1941 1956
30. P. Moreau, M. Attal, and F. Garban Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM trials Leukemia 21 2007 2020 2024
31. J. De Vos, T. Thykjaer, and K. Tarte Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays Oncogene 21 2002 6848 6857
32. E. Terpos, E. Katodritou, and E. Tsiftsakis Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration Haematologica 94 2009 372 379